Enzo Biochem: Hamid Erfanian, Kara Cannon

Sep 06, 2023

Hamid Erfanian has resigned as CEO and director of Enzo Biochem, effective Sept. 5. He had led the company since 2021, overseeing the divestiture of Enzo Clinical Lab to Labcorp earlier this year. No reasons for his departure were provided. Previously, Erfanian was chief commercial officer at PerkinElmer's Euroimmun. Kara Cannon, Enzo's chief operating officer, is assuming the role of interim CEO.

Breaking News

FDA Grants Emergency Use Authorizations for Point-of-Care COVID Tests from Tangen Biosciences, SD Biosensor
Top Five Articles on GenomeWeb Last Week: FDA Proposal for LDT Oversight, Adela $48M Financing, More
FDA Grants Marketing Authorization for Invitae Hereditary Cancer DNA Sequencing Test
Compact Gene Editing Enzyme May Improve Success Rates of Gene Therapies
People in the News at Veracyte, Invitae, Mount Sinai, InterVenn Biosciences, Applied BioCode, More

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.